Fredun Nariman Medhora

Fredun Pharmaceuticals Board recommends 2:1 bonus issue of equity shares, subject to shareholder approval. The bonus issue aims to reward shareholders and signal confidence in future growth and scalab

Fredun Pharmaceuticals reported FY26 standalone revenue of ₹639.12 Cr, up 40.08% YoY, with PAT surging 59.59% to ₹33.21 Cr. EBITDA grew 72.05% YoY to ₹94.79 Cr, with margins expanding 276 bps to 14.83